Cephalosporins in Cutaneous Infections

ABSTRACT: The safety and efficacy of ceftazidime administered as 0.5 g every 8 hours (q8h) or 1.0 g q8h for at least 5 days were compared in 197 patients and found to be effective in the treatment of cellulitis. abscesses, skin ulcers, and wound infections. Staphylococcus aureus was the predominant pathogen in both treatment groups with approximately half of the isolates from each treatment group being gram‐positive. Pseudomonas aeruginosa was the most common gram‐negative isolate. P. aeruginosa, Proteus mirabilis, and Escherichia coli each comprised 5–12% of the isolates from each treatment group. Clinical cure or improvement was achieved in 98.7% of the patients in each treatment group. Concurrently with clinically successful treatment, a high rate of bacteriologic eradication without superinfection was achieved with the 0.5‐g regimen (84% of all isolates) and the 1.0‐g regimen (92%).

[1]  R. Haddad,et al.  Ceftazidime as single-entity therapy for osteomyelitis and infections of skin and skin structures , 1985 .

[2]  R. Baker,et al.  Correlation of in vitro activities of cephalothin and ceftazidime with their efficacies in the treatment of Staphylococcus aureus endocarditis in rabbits , 1984, Antimicrobial Agents and Chemotherapy.

[3]  H. Neu,et al.  Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria. , 1984, Archives of internal medicine.

[4]  E. Estey,et al.  Coagulation Abnormalities Induced by β-Lactam Antibiotics in Cancer Patients , 1983 .

[5]  D. Gibson,et al.  Persistence in serum and lungs of guinea pigs of erythromycin, gentamicin, chloramphenicol and rifampicin and their in-vitro activities against Legionella pneumophila. , 1983, The Journal of antimicrobial chemotherapy.

[6]  C. Kaye,et al.  The penetration of trimethoprim and sulphamethoxazole into synovial fluid. , 1983, The Journal of antimicrobial chemotherapy.

[7]  J. Ayrton,et al.  Pharmacokinetics of ceftazidime in male and female volunteers , 1983, Antimicrobial Agents and Chemotherapy.

[8]  H. Schassan,et al.  Penetration of eight beta-lactam antibiotics into the peritoneal fluid. A pharmacokinetic investigation. , 1983, Archives of surgery.

[9]  C. Park,et al.  Ceftazidime therapy of serious bacterial infections , 1983, Antimicrobial Agents and Chemotherapy.

[10]  A. Saito.  Studies on absorption, distribution, metabolism and excretion of ceftazidime in Japan. , 1983, The Journal of antimicrobial chemotherapy.

[11]  H. Lode,et al.  Multiple dose pharmacokinetics and therapeutic results with ceftazidime. , 1983, The Journal of antimicrobial chemotherapy.

[12]  T. Fredriksen,et al.  Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. , 1983, The Journal of antimicrobial chemotherapy.

[13]  E. Estey,et al.  Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. , 1983, The Journal of infectious diseases.

[14]  A. P. Panwalker,et al.  Hemorrhage, diarrhea, and superinfection associated with the use of moxalactam. , 1983, The Journal of infectious diseases.

[15]  G. Wauters,et al.  The treatment of bone infections with ceftazidime. , 1983, The Journal of antimicrobial chemotherapy.

[16]  T. Russell,et al.  Coagulopathy associated with the use of moxalactam. , 1982, JAMA.

[17]  H. Linderholm,et al.  Ceftazidime: pharmacokinetics in patients and effects on the renal function. , 1982, The Journal of antimicrobial chemotherapy.

[18]  H. Neu,et al.  Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa , 1982, Antimicrobial Agents and Chemotherapy.

[19]  R. Wise,et al.  The penetration of cefoxitin into peritoneal fluid. , 1981, The Journal of antimicrobial chemotherapy.

[20]  D. Turk,et al.  Transferable multiple antibiotic resistance in Haemophilus influenzae. , 1981, The Journal of antimicrobial chemotherapy.

[21]  R. Wise,et al.  Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations , 1981, Antimicrobial Agents and Chemotherapy.

[22]  G. Bodey,et al.  Comparative in vitro study in new cephalosporins , 1981, Antimicrobial Agents and Chemotherapy.

[23]  D. Tanphaichitra,et al.  The combination of pivmecillinam and pivampicillin in the treatment of acute enteric fever. , 1981, The Journal of antimicrobial chemotherapy.

[24]  I. Chopra,et al.  The tetracyclines: prospects at the beginning of the 1980s. , 1981, The Journal of antimicrobial chemotherapy.

[25]  R. Holt,et al.  Hypoprothrombinemia Associated with Moxalactam Treatment of a Septic Sternoclavicular Arthritis Due to Citrobacter Diversus , 1981, Drug intelligence & clinical pharmacy.

[26]  I. Phillips,et al.  Ceftazidime: in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics. , 1981, The Journal of antimicrobial chemotherapy.

[27]  A. Munro,et al.  Pharmacokinetics of ceftazidime in normal subjects. , 1981, The Journal of antimicrobial chemotherapy.

[28]  J. Ayrton,et al.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. , 1981, The Journal of antimicrobial chemotherapy.

[29]  R. Jones,et al.  Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. , 1981, The Journal of antimicrobial chemotherapy.

[30]  J. Andrews,et al.  The pharmacokinetics and tissue penetration of ceftazidime and cefamandole in healthy volunteers. , 1981, The Journal of antimicrobial chemotherapy.

[31]  P. B. Harper.  The in-vitro properties of ceftazidime. , 1981, The Journal of antimicrobial chemotherapy.

[32]  J. Verhaegen,et al.  GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae , 1980, Antimicrobial Agents and Chemotherapy.

[33]  D. M. Ryan,et al.  GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity , 1980, Antimicrobial Agents and Chemotherapy.

[34]  L. Parish,et al.  The Decubitus Ulcer , 1979, International journal of dermatology.

[35]  H. Meislin,et al.  Cutaneous abscesses. Anaerobic and aerobic bacteriology and outpatient management. , 1977, Annals of internal medicine.

[36]  D. Francis,et al.  Pasteurella multocida. Infections after domestic animal bites and scratches. , 1975 .

[37]  H. Fry.  The incidence of surgical wound infection: a prospective study of 20,822 operations , 1974 .